Galecto Stock Today
| GLTO Stock | USD 5.30 0.21 3.81% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Galecto is selling at 5.30 as of the 1st of December 2024; that is 3.81 percent decrease since the beginning of the trading day. The stock's open price was 5.51. Galecto has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Galecto are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of November 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of October 2020 | Category Healthcare | Classification Health Care |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts. Galecto operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.32 M outstanding shares of which 9.47 K shares are currently shorted by private and institutional investors with about 0.57 trading days to cover. More on Galecto
Moving together with Galecto Stock
Moving against Galecto Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Galecto Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsGalecto can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Galecto's financial leverage. It provides some insight into what part of Galecto's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Galecto (GLTO) is traded on NASDAQ Exchange in USA. It is located in Ole Maaloes Vej 3, Copenhagen, Denmark, 2200 and employs 13 people. Galecto is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.26 M. Galecto conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.32 M outstanding shares of which 9.47 K shares are currently shorted by private and institutional investors with about 0.57 trading days to cover.
Galecto currently holds about 79.03 M in cash with (36.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.11.
Check Galecto Probability Of Bankruptcy
Ownership AllocationGalecto retains 3.45 (percent) of its outstanding shares held by insiders and 12.03 (percent) owned by outside corporations.
Check Galecto Ownership Details
Galecto Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jpmorgan Chase & Co | 2024-06-30 | 3 K | |
| Simplex Trading, Llc | 2024-06-30 | 647 | |
| Royal Bank Of Canada | 2024-06-30 | 193 | |
| Group One Trading, Lp | 2024-06-30 | 68.0 | |
| Harbour Investments, Inc. | 2024-09-30 | 8.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Northern Trust Corp | 2024-09-30 | 0.0 | |
| Bridgeway Capital Management, Llc | 2024-06-30 | 0.0 | |
| Spire Wealth Management | 2024-09-30 | 0.0 | |
| Susquehanna International Group, Llp | 2024-06-30 | 168.4 K | |
| Novo A/s | 2024-09-30 | 99.9 K |
Galecto Historical Income Statement
Galecto Stock Against Markets
Galecto Corporate Management
| Garrett Esq | General VP | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Ulf Nilsson | CoFounder | Profile | |
| Hakon Leffler | CoFounder | Profile | |
| Lori Firmani | Interim Officer | Profile | |
| Anders Pedersen | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galecto. If investors know Galecto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galecto listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.11) | Return On Assets (0.34) | Return On Equity (0.73) |
The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galecto's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.